Abstract Introduction: In Cuba, lung cancer represents the first cause of mortality for both
sexes. Non-small cell lung cancer (NSCLC) is the most prevalent histology. Overall, 75-85 …

Purpose: EGFR is a well-validated target for patients with non–small cell lung cancer
(NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant …

In spite of the advances in immunotherapy and targeted therapies, lung cancer continues to
be the leading cause of cancer-related death. The epidermal growth factor receptor is an …

Introduction: Lung cancer represents the most common cause of cancer death worldwide.
While the prognosis remains poor, immunotherapy is giving a positive impact on survival …

Lung cancer is the common fatal illness with the highest incidence and mortality globally.
Epidermal growth factor receptor overexpression by tumor cells is associated with …

Lung cancer remains one of the leading causes of cancer-related deaths. Non–small cell
lung cancer (NSCLC) is the most common histologic type of lung cancer. Medical and …

Advanced non-small cell lung cancer (NSCLC) has faced a therapeutic revolution with the
advent of tyrosine kinase inhibitors (TKIs) and immune checkpoints inhibitors (ICIs) …

Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors and its
role in the development of non-small-cell lung cancer (NSCLC) is widely documented …

Introduction CIMAvax EGF is a therapeutic anticancer vaccine developed entirely in Cuba
and licensed in Cuba for use in adult patients with stage IIIB/IV non-small-cell lung cancer …

Background CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy
which has shown survival benefit as a switch maintenance treatment after platinum-based …